E-poster No. / 壁報編號
B24
Title / 題目
Sacituzumab govitecan in HR-positive/HER2-negative breast cancer cells with resistance to PI3K or AKT inhibitors
First Author / 第一作者
Wei-Pang Chung
Institution / 單位
1 Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
2 Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.
Audio / 音訊檔
Author Group / 作者群
Wei-Pang Chung1,2, Wei-Lun Huang2, 3, Chun-Hui Lee1, 2, 4, Hui-Ping Hsu5, Kuo-Ting Lee5, Zhu-Jun Loh5, Wan-Ling Huang2, You-Yu Liu2,6
Author Group Institution/ 作者群單位
1 Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
2 Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.
3 Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
4 Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
5 Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
6 Institute of Basic Medical Science, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Category / 主題分類
Basic Research
Keyword / 關鍵字
Breast cancer, HR-positive/HER2-negative, TROP2, PI3K, AKT, antibody-drug conjugate, resistance